7B27
RBD domain SARS-CoV2 in complex with neutralizing nanobody NM1230
This is a non-PDB format compatible entry.
Summary for 7B27
| Entry DOI | 10.2210/pdb7b27/pdb |
| Descriptor | Surface glycoprotein, neutralizing nanobody NM1230, 2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total) |
| Functional Keywords | sars-cov2, receptor binding domain, complex structure, neutralizing nanobody, viral protein |
| Biological source | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) More |
| Total number of polymer chains | 4 |
| Total formula weight | 81319.46 |
| Authors | Ostertag, E.,Zocher, G.,Stehle, T. (deposition date: 2020-11-26, release date: 2021-05-12, Last modification date: 2024-10-16) |
| Primary citation | Wagner, T.R.,Ostertag, E.,Kaiser, P.D.,Gramlich, M.,Ruetalo, N.,Junker, D.,Haering, J.,Traenkle, B.,Becker, M.,Dulovic, A.,Schweizer, H.,Nueske, S.,Scholz, A.,Zeck, A.,Schenke-Layland, K.,Nelde, A.,Strengert, M.,Walz, J.S.,Zocher, G.,Stehle, T.,Schindler, M.,Schneiderhan-Marra, N.,Rothbauer, U. NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies. Embo Rep., 22:e52325-e52325, 2021 Cited by PubMed Abstract: In light of the COVID-19 pandemic, there is an ongoing need for diagnostic tools to monitor the immune status of large patient cohorts and the effectiveness of vaccination campaigns. Here, we present 11 unique nanobodies (Nbs) specific for the SARS-CoV-2 spike receptor-binding domain (RBD), of which 8 Nbs potently inhibit the interaction of RBD with angiotensin-converting enzyme 2 (ACE2) as the major viral docking site. Following detailed epitope mapping and structural analysis, we select two inhibitory Nbs, one of which binds an epitope inside and one of which binds an epitope outside the RBD:ACE2 interface. Based on these, we generate a biparatopic nanobody (bipNb) with viral neutralization efficacy in the picomolar range. Using bipNb as a surrogate, we establish a competitive multiplex binding assay ("NeutrobodyPlex") for detailed analysis of the presence and performance of neutralizing RBD-binding antibodies in serum of convalescent or vaccinated patients. We demonstrate that NeutrobodyPlex enables high-throughput screening and detailed analysis of neutralizing immune responses in infected or vaccinated individuals, to monitor immune status or to guide vaccine design. PubMed: 33904225DOI: 10.15252/embr.202052325 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.902 Å) |
Structure validation
Download full validation report
